World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
27175
World Ranking
19013
National Ranking
9478

Overview

John M. Vierling is affiliated with Baylor College of Medicine in the United States. Their research primarily focuses on medicine, with an emphasis on hepatology, epidemiology, surgery, pulmonary and respiratory medicine, and oncology. Within these fields, Vierling has significantly contributed to multiple subfields and topics related to liver diseases and treatments.

The main topics of their work include:

  • Liver Disease Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Pediatric Hepatobiliary Diseases and Treatments
  • Liver Disease and Transplantation
  • Gallbladder and Bile Duct Disorders
  • Organ Transplantation Techniques and Outcomes
  • Hepatitis C virus research

Vierling has published extensively, with a concentration of works appearing in key journals such as:

  • Journal of Hepatology
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Alimentary Pharmacology & Therapeutics
  • Clinical Transplantation

Some recent publications featuring their contributions include:

  • Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis (2023), New England Journal of Medicine
  • A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis (2024), New England Journal of Medicine
  • A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA (2021), Journal of Hepatology
  • A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023), Journal of Hepatology
  • Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group (2022), Journal of Hepatology

Frequent collaborators in Vierling's research include:

  • Cynthia Levy
  • Christopher L. Bowlus
  • Gideon M. Hirschfield
  • Marlyn J. Mayo
  • Kris V. Kowdley

Vierling's scholarly output encompasses over 150 publications in medicine, with 51 specifically in hepatology, reflecting a targeted expertise in liver-related conditions and treatment modalities.

Best Publications

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • Diagnosis and management of autoimmune hepatitis.

    Michael P. Manns;Albert J. Czaja;James D. Gorham;Edward L. Krawitt

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.

    Cara L. Mack;David Adams;David N. Assis;Nanda Kerkar

  • Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients

    M. Eric Gershwin;Carlo Selmi;Carlo Selmi;Howard J. Worman;Ellen B. Gold

  • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

    Marc Bourlière;Stuart C. Gordon;Steven L. Flamm;Curtis L. Cooper

  • Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

    Ulrich H W Beuers;M Eric Gershwin;Robert G Gish;Pietro Luigi Invernizzi

  • Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

    Fred Poordad;Eugene R. Schiff;John M. Vierling;Charles Landis

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

    Marc G. Ghany;Brick Ayola;Federico G. Villamil;Robert G. Gish

  • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial

    Kris V Kowdley;Eric Lawitz;Israel Crespo;Tarek Hassanein

  • Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

    Ira M. Jacobson;Robert S. Brown;Bradley Freilich;Nezam Afdhal

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

    Robert J. Fontana;Hie Won L. Hann;Robert P. Perrillo;John M. Vierling

  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

    Andrew J. Muir;Mitchell L. Shiffman;Atif Zaman;Boris Yoffe

  • Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

    Eugene Schiff;Cjing Lung Lai;Stephanos Hadziyannis;Peter Nuehaus

  • 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

    Marla C Dubinsky;Eric A Vasiliauskas;Hardeep Singh;Maria T Abreu

  • Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

    Paul Kwo;Edward J. Gane;Cheng Yuan Peng;Brian Pearlman

  • Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease

    K A Papadakis;R Matuk;M T Abreu;E A Vasiliauskas

Frequent Co-Authors

John A. Goss
John A. Goss Baylor College of Medicine
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Ira M. Jacobson
Ira M. Jacobson New York University
Bruce R. Bacon
Bruce R. Bacon Saint Louis University
Gideon M. Hirschfield
Gideon M. Hirschfield University Health Network
M. Eric Gershwin
M. Eric Gershwin University of California, Davis
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Andrew J. Muir
Andrew J. Muir Duke University
Michael P. Manns
Michael P. Manns Hannover Medical School
David Jones
David Jones Newcastle University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare but unsure about Medical School, online degrees can offer flexible and rewarding career paths. For example, earning an online nutrition degree allows you to explore dietetics, wellness coaching, and public health education from anywhere.

Those seeking leadership roles may consider online mha programs that develop expertise in hospital and healthcare management. These programs prepare you for administrative positions, policy development, or health services management.

Nurses looking to advance can find flexible options through rn to bsn without clinicals programs, allowing registered nurses to gain a Bachelor of Science in Nursing entirely online, often at an accelerated pace.

For nursing professionals who want to reach the top of their field, the shortest dnp programs online offer a direct route to advanced practice, leadership, and faculty roles.

These online pathways make it easier to balance work, study, and other commitments—helping you enter, advance, or specialize within the field of healthcare.

Best Scientists Citing John M. Vierling

Trending Scientists